ST天圣(002872) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥292,060,015.82, a decrease of 38.48% compared to ¥474,746,180.04 in the same period last year[9] - The net profit attributable to shareholders was a loss of ¥8,586,532.25, representing a decline of 181.50% from a profit of ¥10,430,895.96 in the previous year[9] - The net cash flow from operating activities decreased by 70.18%, down to ¥15,211,693.01 from ¥51,010,099.91 year-on-year[9] - Basic and diluted earnings per share were both -¥0.0270, a drop of 181.57% from ¥0.0328 in the same period last year[9] - Total operating revenue for Q1 2020 was CNY 292,060,015.82, a decrease from CNY 474,746,180.04 in the previous period[48] - The net profit for Q1 2020 was a loss of ¥9,853,331.57, compared to a profit of ¥11,174,338.27 in Q1 2019, representing a significant decline[51] - The total comprehensive income for Q1 2020 was -¥9,853,331.57, down from ¥11,174,338.27 in Q1 2019[51] - The company's operating profit for Q1 2020 was -¥8,291,467.56, compared to ¥16,613,835.76 in the same period last year[51] - The company reported a significant increase in sales expenses, which rose to ¥37,529,782.07 in Q1 2020 from ¥11,810,939.64 in Q1 2019[53] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,282,876,673.21, a decrease of 2.47% from ¥4,391,461,194.04 at the end of the previous year[9] - Total assets as of March 31, 2020, amounted to CNY 4,024,974,042.55, compared to CNY 4,009,557,716.90 at the end of 2019[45] - Total liabilities as of March 31, 2020, were CNY 877,385,745.43, slightly up from CNY 865,721,709.20 in the previous period[46] - The total liabilities of the company amounted to 1,437,238,285.41 yuan, with total assets of 4,391,461,194.04 yuan, indicating a healthy asset-to-liability ratio[66] - The company’s total equity was reported at 2,954,222,908.63 yuan, reflecting a stable financial position[66] Cash Flow - The cash flow from operating activities for Q1 2020 was ¥15,211,693.01, down from ¥51,010,099.91 in the previous year[58] - The company reported a total cash inflow from operating activities of 277,338,684.06 yuan, compared to 243,510,035.64 yuan in the previous period[61] - Total cash inflow from investment activities was 90,339,500.00 yuan, while cash outflow was 67,810,096.31 yuan, resulting in a net cash flow of 22,529,403.69 yuan from investments[61] - Cash inflow from financing activities totaled 174,961,904.80 yuan, with cash outflow of 209,677,089.96 yuan, leading to a net cash flow of -34,715,185.16 yuan from financing[62] - The ending balance of cash and cash equivalents was 106,869,232.96 yuan, down from 150,566,451.58 yuan at the beginning of the period[62] Legal and Compliance Issues - The company received a warning for delisting risk due to an audit report from Beijing Xinghua Accounting Firm, which issued an opinion of inability to express for the 2018 financial report[18] - The controlling shareholder Liu Qun and former executives have not fully fulfilled their commitment to increase shareholding, with only one of the four individuals completing the increase as of the report date[18] - The company was fined a total of RMB 3.8 million for unit bribery and has been ordered to repay RMB 91.82 million for embezzled funds, with the final judgment still pending[19] - The company’s stock trading has been subject to additional risk warnings due to the ongoing legal issues involving its controlling shareholder[21] - The company has been involved in significant litigation, with the first-instance judgment still not finalized, indicating ongoing legal uncertainties[19] Shareholder and Management Actions - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[14] - The company signed a share transfer intention agreement with Chongqing Pharmaceutical Group, planning to transfer part of its pharmaceutical commercial company shares[22] - The company is actively monitoring the legal case and will disclose information based on the progress of the repayment of misappropriated funds[21] - The company plans to strengthen internal controls and compliance training to prevent future fund misappropriation incidents[34] - The company is committed to fulfilling its obligations regarding share price stabilization measures as outlined in its public offering prospectus[26] Research and Development - Research and development expenses for Q1 2020 were CNY 4,029,596.06, a decrease from CNY 5,615,898.02 in the previous period[49] - Research and development expenses for Q1 2020 were ¥477,098.31, a decrease of 78.8% from ¥2,248,879.98 in Q1 2019[53] Miscellaneous - The company has no securities investment during the reporting period, reflecting a conservative investment strategy[28] - There were no violations regarding external guarantees, ensuring compliance with regulatory requirements[31] - The company has not completed the share repurchase commitment due to various reasons, including legal issues faced by some executives[26] - The company has disclosed multiple announcements regarding the legal and financial issues, including the status of the asset restructuring plan[23]